iRadimed (NASDAQ:IRMD) CFO John Glenn Sells 15,000 Shares

by · The Markets Daily

iRadimed Corporation (NASDAQ:IRMD – Get Free Report) CFO John Glenn sold 15,000 shares of the business’s stock in a transaction that occurred on Thursday, December 11th. The stock was sold at an average price of $97.29, for a total transaction of $1,459,350.00. Following the completion of the sale, the chief financial officer directly owned 7,362 shares of the company’s stock, valued at $716,248.98. This represents a 67.08% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website.

iRadimed Stock Performance

Shares of iRadimed stock traded down $1.15 during midday trading on Friday, reaching $96.23. 64,845 shares of the company’s stock traded hands, compared to its average volume of 51,248. iRadimed Corporation has a 52 week low of $47.48 and a 52 week high of $98.44. The company’s 50 day simple moving average is $83.66 and its 200 day simple moving average is $71.15. The company has a market cap of $1.22 billion, a price-to-earnings ratio of 58.32 and a beta of 1.06.

iRadimed (NASDAQ:IRMD – Get Free Report) last issued its quarterly earnings data on Monday, November 3rd. The medical equipment provider reported $0.47 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.43 by $0.04. iRadimed had a net margin of 26.31% and a return on equity of 22.93%. The firm had revenue of $21.20 million during the quarter, compared to analysts’ expectations of $20.50 million. iRadimed has set its Q4 2025 guidance at 0.470-0.510 EPS and its FY 2025 guidance at 1.840-1.880 EPS. As a group, equities research analysts predict that iRadimed Corporation will post 1.66 earnings per share for the current year.

iRadimed Announces Dividend

The business also recently announced a special dividend, which will be paid on Tuesday, December 30th. Investors of record on Wednesday, December 17th will be issued a $0.50 dividend. The ex-dividend date is Wednesday, December 17th. iRadimed’s payout ratio is 41.21%.

Wall Street Analyst Weigh In

Several brokerages have commented on IRMD. Roth Capital set a $90.00 price target on iRadimed in a report on Friday, October 31st. Lake Street Capital reaffirmed a “buy” rating and set a $100.00 price objective on shares of iRadimed in a report on Monday, November 3rd. Zacks Research upgraded shares of iRadimed to a “hold” rating in a report on Tuesday, November 4th. Wall Street Zen lowered shares of iRadimed from a “strong-buy” rating to a “buy” rating in a research report on Sunday, October 26th. Finally, Weiss Ratings reaffirmed a “buy (b-)” rating on shares of iRadimed in a research report on Wednesday. Four investment analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $87.33.

Get Our Latest Analysis on IRMD

Institutional Investors Weigh In On iRadimed

Several hedge funds have recently made changes to their positions in IRMD. CWM LLC increased its stake in iRadimed by 62.2% during the third quarter. CWM LLC now owns 550 shares of the medical equipment provider’s stock valued at $39,000 after acquiring an additional 211 shares during the period. Quarry LP bought a new stake in shares of iRadimed in the 3rd quarter worth approximately $40,000. State of Alaska Department of Revenue acquired a new stake in shares of iRadimed during the 3rd quarter worth approximately $47,000. Tower Research Capital LLC TRC increased its position in shares of iRadimed by 191.1% during the second quarter. Tower Research Capital LLC TRC now owns 754 shares of the medical equipment provider’s stock valued at $45,000 after purchasing an additional 495 shares during the period. Finally, Spire Wealth Management acquired a new position in shares of iRadimed in the second quarter valued at $60,000. Institutional investors own 92.34% of the company’s stock.

iRadimed Company Profile

(Get Free Report)

IRadimed Corp. engages in the development, manufacture, marketing, and distribution of Magnetic Resonance Imaging compatible medical devices. It also provides a non-magnetic Intravenous infusion pump system that is specifically designed for use during MRI procedures. The company was founded by Roger Susi in July 1992 and is headquartered in Winter Springs, FL.

Recommended Stories